Cationic binder, pharmaceutical composition comprising the same and method of using the same
AssigneesChanghua Christian Medical Foundation Changhua Christian Hospital, National Chung Hsing University
InventorsJun-Yen Uan, Hung-Ming Wu
Life of this patent
Estimating the term…
Abstract
The present invention provides a pharmaceutical composition for treating a patient suffering from or predisposed to hyperphosphatemia, which contains Mg—Fe—Cl HCln. In one embodiment, the Mg—Fe—Cl HCln is shown in formula (I). The phosphorus uptaking capacity of the pharmaceutical composition is greater than 100 ppm/(g/L). The present invention further provides a method for treating a patient suffering from or predisposed to hyperphosphatemia by using said pharmaceutical composition. The present invention further provides a method of manufacturing the pharmaceutical composition.
Claims20
A cationic binder, comprising magnesium, iron (III), H2O and chloride, and an atomic ratio of Mg+2 and Fe+3 from raw materials used for synthesizing the cationic binder is between 2:1 and 60:1, and an anion uptaking capacity of the cationic binder is greater than 100 ppm/(g/L), wherein a ratio of H2O:(Fe3++Mg2+) in the cationic binder is between 0.0315 and 0.152.
A pharmaceutical composition for treating a patient suffering from or predisposed to hyperphosphatemia, comprising a cationic binder and a pharmaceutically acceptable carrier, wherein the cationic binder comprises magnesium, iron(III) H2O and chloride, and an atomic ratio of Mg+2 and Fe+3 from raw materials used for synthesizing the cationic binder is between 2:1 and 60:1, and a anion uptaking capacity of the cationic binder is greater than 100 ppm/(g/L).
The method according to 15, wherein a dosage of the pharmaceutical composition is between 20 mg/kg and 30 mg/kg.
Dependencies are inferred from the claim text.